BPC-157 is a 15-amino-acid gastric-derived pentadecapeptide investigated for tendon / soft-tissue repair, GI mucosal protection, and NO-pathway modulation. Sermorelin is a synthetic GHRH 1–29 analog investigated for GH-axis stimulation (Reutens 1996, Walker 1994) and historically used only for pediatric GH-deficiency diagnostic-stimulation testing. BPC-157 has the more ambitious mechanism claim (local wound healing, GI protection, angiogenic) but zero human RCTs in any indication; Sermorelin has a narrower mechanism (upstream GHRH-receptor amplification in healthy adults and pediatric diagnostic testing) and was withdrawn from the US market in 2008. Online, both peptides show up together in wellness-clinic "anti-aging stacks" — the comparison matters because the two mechanisms are non-complementary, the WADA classifications differ (S0 vs S2), and neither has efficacy data for the outcomes driving interest.
The asymmetric-evidence verdict this comparison surfaces: BPC-157 has the broader mechanism ambition (wound healing + GI + angiogenic) but zero human RCTs in any indication in any delivery route. Sermorelin has a narrower mechanism (upstream GHRH-receptor amplification) and a real, narrowly-bounded 1990s human pharmacodynamic trail — but only for diagnostic-stimulation endpoints in pediatric GH deficiency (Reutens 1996) and GH pulsatility in healthy adults (Walker 1994), not for any of the body-composition / anti-aging outcomes driving current interest. This page does not introduce new citations. It maps the existing BPC-157 and Sermorelin deep-dive evidence onto the WADA-asymmetric, mechanism-non-complementary evidence gap — the gap that uniquely matters for this pair because both peptides are routinely bundled in peptide-clinic "anti-aging stacks" without distinguishing whether either peptide has efficacy data for the indication it's being prescribed for, or whether the two mechanisms overlap in any way. PMIDs reused here come from the BPC-157 and Sermorelin deep-dives only — no new citations introduced.
Each row states a claim that is supported by a specific peer-reviewed citation where one exists, or by an established mechanistic class where the mechanism is shared. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | BPC-157 evidence | Sermorelin evidence |
|---|---|---|
| Mechanism / plausible target | Strong (mechanistic)BPC-157 is a 15-AA stable gastric pentadecapeptide. Proposed mechanisms: modulation of the nitric oxide (NO) system, VEGFR2 upregulation driving angiogenesis, EGR1 / growth-factor signaling, and counter-action of NO-synthase inhibition. Sikiric 1997 foundational NO-pathway paper; reviewed in PMID: 9493769 | Strong (mechanistic)Sermorelin acetate is a synthetic 1–29 fragment of GHRH (growth hormone-releasing hormone). It binds the GHRH receptor in the pituitary, amplifying the natural GH-pulse architecture rather than overriding it. Walker 1994 characterized the GH-pulse amplification in healthy adults. |
| Wound healing / soft-tissue repair | Animal onlySikiric lab rodent Achilles tendon, MCL, and dermal wound models — replicated across multiple injury models. Documented tendon fibroblast outgrowth. PMID: 32628526; PMID: 31800443 | Not establishedNo wound-healing or soft-tissue repair evidence published for Sermorelin. The GHRH-receptor-mediated GH-pulse amplification does not act at the local injury-repair pathway; pharmacokinetic profile (subcutaneous/intranasal) does not concentrate Sermorelin at the wound site. |
| GI mucosal protection / ulcer healing | Animal onlySikiric lab NSAID- and ethanol-induced gastric damage models document counteraction of gastric lesions. The peptide is gastric-derived; the claimed GI-protective effect recapitulates the endogenous BPC-157 role in gastric juice. PMID: 32628526 | Not establishedNo published GI mucosal or ulcer-healing evidence for Sermorelin. Sermorelin targets the pituitary GHRH receptor; mechanism does not extend to GI epithelial repair. GH itself has no characterized GI-protective effect in adult humans. |
| Angiogenesis / vascular support | Animal onlyVEGFR2 upregulation in rodent injury models; documented new-vessel formation around healing tissues across Sikiric lab studies. PMID: 34139902 | Indirect onlyNo direct angiogenic evidence for Sermorelin. GH / IGF-1 axis regulation has indirect vascular effects in endocrine contexts (acromegaly, GH-deficiency replacement) — but these are systemic endocrine effects, not the local angiogenic action claimed for BPC-157. |
| Body composition / muscle growth / fat loss | NoneBPC-157 is not marketed or studied for body composition / muscle growth / fat loss in humans or in robust animal models. The mechanism (local NO-pathway modulation) does not extend to systemic anabolic pathways. | Pharmacodynamic only, no efficacy RCTSermorelin amplifies GH pulsatility (Walker 1994), but body composition outcomes (lean mass, fat mass, strength) in healthy adults from sustained Sermorelin use have never been tested in a randomized efficacy trial. Mechanism ≠ efficacy — GH pulse amplification does not establish downstream anabolic outcomes. |
| Anti-aging / longevity outcomes | NoneNo published anti-aging / longevity evidence for BPC-157. The mechanism (local NO modulation, VEGFR2) is regenerative, not longevity-oriented. | Pharmacodynamic only, no efficacy RCTSermorelin is sold in peptide clinics under "anti-aging" framing, but no human RCT for adult longevity / skin quality / energy / cognitive preservation has been published. The 2008 US market withdrawal was for commercial reasons (limited pediatric diagnostic population), not safety. |
| Sleep / recovery optimization | NoneNo published sleep / recovery evidence for BPC-157. Mechanism (local NO modulation) does not extend to CNS sleep architecture. | Pharmacodynamic speculation onlyGH pulse architecture overlaps with slow-wave sleep physiologically; Sermorelin-induced GH-pulse amplification has plausible (but untested) sleep-axis effects. No published human RCT for sleep quality from Sermorelin in healthy adults. |
| Human randomized controlled trial (any indication) | NoneZero published peer-reviewed human RCTs for BPC-157 efficacy for any indication as of August 2026. Animal evidence (rodent wound healing, GI mucosal protection, VEGFR2 angiogenic) is the only available evidence class. | Diagnostic-stimulation trials onlyTwo human RCTs: Reutens 1996 (pediatric GH-deficiency diagnostic stimulation, n limited) and Walker 1994 (healthy adult GH pulsatility, n limited). PMID: 8834260; PMID: 7527273. No efficacy RCT for any adult anti-aging / body-comp indication. |
| Reproducibility / lab breadth | Single-lab dominantThe overwhelming majority of positive BPC-157 animal data comes from the Sikiric lab at the University of Zagreb — one lab with patent interests in BPC-157 derivatives. Independent replication by other major research institutions has been limited. This is documented in the Sikiric 2021 review (PMID: 34139902). | Multi-group, 1990s programSermorelin's diagnostic-stimulation and pharmacodynamic evidence was generated by multiple independent groups during the 1990s Geref / Geri-3 cycle (Serono / EMD Serono). The data is older but multi-source for the limited endpoints it covers. |
| WADA status | Prohibited (S0 — non-approved substances, at all times) — explicitly named alongside other pentadecapeptides. TUE pathway closed for any indication. | Prohibited (S2 — Peptide Hormones, GH-Releasing Factors subcategory, in-competition and out-of-competition) — Sermorelin is explicitly listed under the GHRF subcategory alongside CJC-1295, Tesamorelin, and the GHRP class. TUE pathway closed. |
| FDA status | Not approved. FDA Category 2 bulk drug substance — the FDA has identified BPC-157 as having no suitable monograph for compounding. Excluded from 503A compounding allowances. Not a recognized active pharmaceutical ingredient for any indication. | Not approved for any current indication. Withdrawn from US market in 2008 (commercial withdrawal, not safety). No compounding monograph. No current adult anti-aging / longevity approval pathway. Tesamorelin (Egrifta) is the only FDA-approved GHRF, for HIV lipodystrophy only. |
| Risk profile | Unknown long-term safety in humans; no human safety database. WADA S0 by athletic regulation. Grey-market supply chain quality varies widely. Sikiric lab COI (patent interests in BPC-157 derivatives) is a documented limitation on evidence replication. | Limited long-term safety data in adults. Withdrawn from US market in 2008 (commercial, not safety). WADA S2 by athletic regulation in- and out-of-competition. Combination-blend prescriptions (Sermorelin + Ipamorelin + CJC-1295) amplify regulatory exposure without any combination efficacy data. |
Citations reused from the existing BPC-157 and Sermorelin deep-dives — BPC-157 PMIDs (34139902 Sikiric 2021 review, 32628526 GI/Msk, 31800443 wound healing, 9493769 foundational NO-pathway) are referenced; Sermorelin PMIDs (8834260 Reutens 1996 diagnostic, 7527273 Walker 1994 GH pulsatility) are referenced — no new citations introduced.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.
Three honest verdicts. Each evaluates the asymmetric-evidence framing: BPC-157 has the broader local-wound-healing mechanism but zero human RCTs in any indication in any delivery route (Sikiric-lab-dominant animal evidence with disclosed COI); Sermorelin has narrower upstream GH-pulse data from a 1990s diagnostic-stimulation trial program (Reutens 1996, Walker 1994) and zero adult anti-aging / body-comp efficacy RCTs. The WADA categories differ (S0 vs S2) but both prohibit at all times for athletes. Choosing one over the other does not establish efficacy for either — it only frames where the evidence is strongest.
BPC-157 has a real mechanism story — NO-pathway modulation (PMID: 9493769), VEGFR2-driven angiogenic action (PMID: 34139902), tendon fibroblast outgrowth (PMID: 32628526), and GI mucosal protection in rodent models (PMID: 31800443). What it does NOT have: any human RCT for any indication in any delivery route, and the entire positive evidence base comes from a single research group (Sikiric, Zagreb) with disclosed patent interests in BPC-157 derivatives. Caveats: WADA S0 (at all times); FDA Category 2 (excluded from 503A compounding); grey-market sourcing quality varies widely; community-reported dosing (subcutaneous / oral / intranasal) does not establish human efficacy. Mechanism is not efficacy.
Sermorelin's strength is that the peptide has a real, narrowly-bounded human-pharmacodynamic data trail — Walker 1994 (JCEM, GH pulsatility in healthy adults, PMID: 7527273) and Reutens 1996 (Clin Endocrinol, pediatric GH-deficient diagnostic stimulation, PMID: 8834260). What it does NOT have: any efficacy RCT for adult anti-aging / body composition / sleep quality / cognitive preservation. Caveats: withdrawn from the US market in 2008 (commercial, not safety); WADA S2 (in- and out-of-competition); no compounding monograph; combination blends (Sermorelin + Ipamorelin + CJC-1295) amplify regulatory exposure without efficacy data. The peptide-clinic "anti-aging" framing extrapolates 1990s pharmacodynamics into adult longevity claims without any controlled trial data bridging the two.
The community rationale for stacking BPC-157 (tendon / wound healing) with Sermorelin (GH-pulse amplifier) is that the two peptides "cover different axes of recovery and longevity". This framing is structurally wrong: BPC-157 has zero human RCTs in any indication, Sermorelin has zero efficacy RCTs for any adult anti-aging / body-comp outcome, and the two peptides operate at non-complementary mechanisms (local NO-pathway / VEGFR2 vs upstream GHRH-receptor / somatotroph GH-pulse). The combination stacks two peptides at non-overlapping pathways, not receptor-complementary stimulation like Sermorelin + Ipamorelin (Sermorelin vs Ipamorelin) or peptide-stacking with shared cascade data. Caveats: the pairing stacks regulatory exposure (BPC-157 is WADA S0; Sermorelin is WADA S2 — two separate violations if both are detected); the community "anti-aging stack" framing conflates evidence SCOPE, not mechanism complementarity; the buyer should not assume either component "covers" the other's evidence gap because the indications each peptide might apply to are not the same indication.
"Evidence tier" is the most important field in every claim above. Two peptides can share "anti-aging" or "recovery" framing while having radically different evidence behind that framing. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S0 for BPC-157, WADA S2 for Sermorelin): BPC-157 is prohibited at all times under WADA S0 (non-approved substances subcategory) — a positive test is a ban with no Therapeutic Use Exemption (TUE) pathway. Sermorelin is prohibited under WADA S2 (peptide hormones / growth factors / GHRFs), both in-competition and out-of-competition — also no TUE. Neither peptide is a candidate for athletic-performance or recovery claims under any WADA jurisdiction. The pairing does not change either peptide's WADA status. A positive test on either peptide is a separate violation — both peptides present is two violations.
Anyone seeking an FDA-approved therapy: neither peptide is FDA-approved for any adult anti-aging, body composition, or systemic recovery indication. BPC-157 is FDA Category 2 (excluded from 503A compounding). Sermorelin was withdrawn from the US market in 2008 (commercial, not safety). No compounding monograph exists for either adult anti-aging protocol. Stacking amplifies regulatory exposure without an evidence base.
Anyone needing proven efficacy for any adult outcome driving interest: BPC-157 has zero human RCTs for any indication in any delivery route as of August 2026. Sermorelin has human pharmacodynamic data only for diagnostic-stimulation endpoints (Reutens 1996) and healthy-adult GH pulsatility (Walker 1994) — no efficacy RCT for any adult anti-aging, body composition, sleep quality, recovery, or longevity outcome. Community-reported outcomes are not clinical evidence. The BPC-157 + Sermorelin "anti-aging stack" does not "cover" the evidence gap; both peptides have evidence bases restricted to the narrow endpoints they were tested on, with no transferability to the popular indications.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.